Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Rosenbaum, V. Chandran (2012)
Management of Comorbidities in Ankylosing SpondylitisThe American Journal of the Medical Sciences, 343
RI Sutherland (1975)
296J Rheumatol, 2
J. Reveille (2006)
The genetic basis of ankylosing spondylitisCurrent Opinion in Rheumatology, 18
Julian Hanson, S. Mirza (2000)
Predisposition for spinal fracture in ankylosing spondylitis.AJR. American journal of roentgenology, 174 1
A. Boonen, Wilfried Mau (2009)
The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis.Clinical and experimental rheumatology, 27 4 Suppl 55
Sutherland Ri, D. Matheson (1975)
Inflammatory involvement of vertebrae in ankylosing spondylitis.The Journal of rheumatology, 2 3
I. Essers, C. Stolwijk, A. Boonen, M. Bruin, M. Bazelier, F. Vries, A. Tubergen (2014)
Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort studyAnnals of the Rheumatic Diseases, 75
Matthew Brown (2007)
Breakthroughs in genetic studies of ankylosing spondylitis.Rheumatology, 47 2
M. Ward (2002)
Functional disability predicts total costs in patients with ankylosing spondylitis.Arthritis and rheumatism, 46 1
C. Mercieca, I. Horst-Bruinsma, A. Borg (2014)
Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practiceCurrent Rheumatology Reports, 16
(1972)
Injury rates by industry 1970, BLS Report 406, Department of Labor, Bureau of Labor Statistics.IMS, Industrial medicine and surgery, 41 12
V. Schabert, C. Watson, G. Joseph, P. Iversen, C. Burudpakdee, D. Harrison (2013)
Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care PopulationJournal of Managed Care Pharmacy : JMCP, 19
A. Boonen (2006)
A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitisNature Clinical Practice Rheumatology, 2
A Boonen (2009)
S112Clin Exp Rheumatol, 27
J. Meesters, A. Bremander, S. Bergman, I. Petersson, A. Turkiewicz, M. Englund (2014)
The risk for depression in patients with ankylosing spondylitis: a population-based cohort studyArthritis Research & Therapy, 16
J. Reveille, A. Ximenes, M. Ward (2012)
Economic Considerations of the Treatment of Ankylosing SpondylitisThe American Journal of the Medical Sciences, 343
Tamar Brionez, J. Reveille (2008)
The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitisCurrent Opinion in Rheumatology, 20
(2016)
Employee tenure in 2016
JD Greenberg (2016)
88J Rheumatol, 43
J. Reveille, M. Weisman (2013)
The Epidemiology of Back Pain, Axial Spondyloarthritis and HLA-B27 in the United StatesThe American Journal of the Medical Sciences, 345
M. Cawley, T. Chalmers, J. Ball (1971)
Destructive lesions of vertebral bodies in ankylosing spondylitis.Annals of the Rheumatic Diseases, 30
Nadeem Ahmed, J. Prior, Ying Chen, R. Hayward, C. Mallen, S. Hider (2016)
Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort studyClinical Rheumatology, 35
A. Bremander, I. Petersson, S. Bergman, M. Englund (2011)
Population‐based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitisArthritis Care & Research, 63
A. Tournadre, Bruno Pereira, A. Lhoste, J. Dubost, J. Ristori, Pascal Claudepierre, Maxime Dougados, M. Soubrier (2013)
Differences Between Women and Men With Recent‐Onset Axial Spondyloarthritis: Results From a Prospective Multicenter French CohortArthritis Care & Research, 65
C. Stolwijk, I. Essers, A. Tubergen, A. Boonen, M. Bazelier, M. Bruin, F. Vries (2014)
The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort studyAnnals of the Rheumatic Diseases, 74
M. Ward, J. Reveille, T. Learch, John Davis, M. Weisman (2008)
Impact of ankylosing spondylitis on work and family life: comparisons with the US population.Arthritis and rheumatism, 59 4
Jiunn-Horng Kang, Yi-Hua Chen, Herng‐Ching Lin (2010)
Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based studyAnnals of the Rheumatic Diseases, 69
J. Taurog, A. Chhabra, R. Colbert (2016)
Ankylosing Spondylitis and Axial Spondyloarthritis.The New England journal of medicine, 374 26
A. Boonen, T. Brinkhuizen, R. Landewé, D. Heijde, J. Severens (2010)
Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal costAnnals of the Rheumatic Diseases, 69
A. Veltri, P. Scarpellini, A. Piccinni, C. Conversano, C. Giacomelli, S. Bombardieri, L. Bazzichi, L. Dell’Osso (2012)
Methodological approach to depressive symptoms in fibromyalgia patients.Clinical and experimental rheumatology, 30 6 Suppl 74
J. Walsh, O. Adejoro, B. Chastek, Yujin Park (2018)
Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database.Journal of comparative effectiveness research, 7 4
I Palla (2012)
S136Clin Exp Rheumatol, 30
J. Palmer, Yunfeng Li, V. Herrera, Y. Tsang, M. Liao, Z. Ozturk (2015)
Treatment Patterns and Costs for Anti-TNFñ Therapy in Patients withAnkylosing Spondylitis, 2015
J. Braun, Mathias Bollow, Gerold Remlinger, U. Eggens, M. Rudwaleit, A. Distler, J. Sieper (1998)
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.Arthritis and rheumatism, 41 1
(US Department of Labor Bureau of Labor Statistics. Employee tenure in 2016. 2016;USDL-16-1867. https://www.bls.gov/news.release/archives/tenure_09222016.pdf)
US Department of Labor Bureau of Labor Statistics. Employee tenure in 2016. 2016;USDL-16-1867. https://www.bls.gov/news.release/archives/tenure_09222016.pdfUS Department of Labor Bureau of Labor Statistics. Employee tenure in 2016. 2016;USDL-16-1867. https://www.bls.gov/news.release/archives/tenure_09222016.pdf, US Department of Labor Bureau of Labor Statistics. Employee tenure in 2016. 2016;USDL-16-1867. https://www.bls.gov/news.release/archives/tenure_09222016.pdf
I. Palla, L. Trieste, C. Tani, R. Talarico, P. Cortesi, M. Mosca, G. Turchetti (2012)
A systematic literature review of the economic impact of ankylosing spondylitis.Clinical and experimental rheumatology, 30 4 Suppl 73
Thomas Hunter (1989)
The spinal complications of ankylosing spondylitis.Seminars in arthritis and rheumatism, 19 3
IntroductionIn addition to the considerable patient and societal burdens, the financial burdens of ankylosing spondylitis (AS) are substantial. Understanding both all-cause and AS-specific direct costs in patients with AS is important if we are to understand the financial impact on patients with AS and payers in the United States. This study assessed both all-cause and AS-specific healthcare utilization and direct costs in US patients with AS using administrative claims data.MethodsAdults aged ≥ 18 years enrolled in the MarketScan® Commercial and Medicare databases with ≥ 1 inpatient or ≥ 2 non-rule-out outpatient diagnoses of AS between January 1, 2013, and December 31, 2013, were included. Patients had continuous enrollment with medical and pharmacy benefits for ≥ 12 months before and after the index date (first diagnosis). Non-AS controls were matched up to 5:1 to patients with AS on age, geographic region, index calendar year, and sex. All-cause and AS-specific healthcare utilization and direct costs were measured during the follow-up period and reported as per patient per year.ResultsPatients with AS (N = 6679) had significantly higher rates of total all-cause inpatient admission (12% vs 6%), emergency department visits (23% vs 15%), nonhospital-based outpatient visits (100% vs 84%), hospital-based outpatient visits (68% vs 46%), other outpatient services (97% vs 81%), and medication use (97% vs 82%) compared with matched controls (N = 19,951). Patients with AS had approximately tenfold higher median total healthcare costs than matched controls ($24,978 vs $2139 per patient per year), largely driven by increased outpatient and pharmacy costs; P < 0.05 for all comparisons. The median (IQR) total AS-specific healthcare costs were $10,250 ($774, $28,824).ConclusionIn this analysis of claims data, increased outpatient and pharmacy costs were key contributors to higher all-cause total healthcare costs in US patients with AS.FundingNovartis Pharmaceuticals Corporation, East Hanover, NJ.Electronic supplementary materialThe online version of this article (10.1007/s40744-018-0124-4) contains supplementary material, which is available to authorized users.
Rheumatology and Therapy – Pubmed Central
Published: Aug 18, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.